(Bloomberg) -- Weight-loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. are more likely to turn into laggards in 2024 than other stock market stars of this year. That’s according to Bloomberg’s latest Markets Live Pulse survey.Most Read from BloombergBitcoin’s 2023 Rally Frays During Brief 7.5% Drop Toward $40,000Stocks Make Cautious Start to Event-Packed Week: Markets WrapHarvard Under Heightened Pressure After Penn Leaders OustedBiden’s Support of Israel Alienates More Democrats in New Poll
In this article, we will take a look at the 12 healthcare stocks billionaires like the most. To skip our analysis of the recent market trends and activity, you can go directly to see the 5 Healthcare Stocks Billionaires Like the Most. The healthcare sector includes companies ranging from pharmaceuticals, medical equipment and device manufacturers, […]
Here's why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Axsome Therapeutics): One promising growth stock that investors may be overlooking today is Axsome Therapeutics. With a market capitalization of around $3.2 billion, this is still a fairly small biotech stock for investors to load up on before it gets much bigger.